Compare COE & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COE | RCEL |
|---|---|---|
| Founded | 2011 | N/A |
| Country | Singapore | United States |
| Employees | N/A | 226 |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.9M | 129.3M |
| IPO Year | 2015 | N/A |
| Metric | COE | RCEL |
|---|---|---|
| Price | $21.65 | $4.11 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.88 |
| AVG Volume (30 Days) | 3.5K | ★ 270.2K |
| Earning Date | 06-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.17 |
| Revenue Next Year | N/A | $49.82 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.32 | $3.22 |
| 52 Week High | $56.13 | $7.12 |
| Indicator | COE | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 39.63 | 44.38 |
| Support Level | $21.50 | $4.00 |
| Resistance Level | $23.50 | $5.75 |
| Average True Range (ATR) | 1.17 | 0.30 |
| MACD | -0.56 | -0.02 |
| Stochastic Oscillator | 25.00 | 17.78 |
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand. The Group operates in seven principal geographical area: China, Hong Kong, Philippines, Singapore, Malaysia, Thailand and Saudi Arabia.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.